Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Clinical trial NCT04666272 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04666272
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2020-12-31
- Primary completion
- 2028-02-04
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.